Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology.

McCutcheon RA. et al, (2024), Lancet Psychiatry

Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes

Stedehouder J. et al, (2024)

Lights, Fiber, Action! A primer on in vivo fiber photometry

WALTON M. et al, (2023), Neuron

Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's.

Brimblecombe KR. et al, (2023), Eur J Neurosci

Axo-glial interactions between midbrain dopamine neurons and oligodendrocyte lineage cells in the anterior corpus callosum.

Caldwell M. et al, (2023), Brain Struct Funct, 228, 1993 - 2006

Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction.

Christie LA. et al, (2023), J Med Chem

Impaired dopamine release in Parkinson's disease.

Cramb KML. et al, (2023), Brain, 146, 3117 - 3132

Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2.

Kosillo P. et al, (2022), Elife, 11

Dopamine Release in Nucleus Accumbens Is under Tonic Inhibition by Adenosine A1 Receptors Regulated by Astrocytic ENT1 and Dysregulated by Ethanol.

Roberts BM. et al, (2022), J Neurosci, 42, 1738 - 1751

Dopamine release in nucleus accumbens is under tonic inhibition by adenosine A1 receptors regulated by astrocytic ENT1 and dysregulated by ethanol

Roberts BM. et al, (2021)

Revisiting dopamine-acetylcholine imbalance in Parkinson's disease: Glutamate co-transmission as an exciting partner in crime.

Zhang Y-F. and Cragg SJ., (2021), Neuron, 109, 1070 - 1071

Axonal Modulation of Striatal Dopamine Release by Local γ-Aminobutyric Acid (GABA) Signalling.

Roberts BM. et al, (2021), Cells, 10

Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of α-Synuclein and Cholesterol.

Threlfell S. et al, (2021), Front Cell Neurosci, 15

GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model.

Roberts BM. et al, (2020), Nat Commun, 11

CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease.

Bengoa-Vergniory N. et al, (2020), Nat Commun, 11

Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice.

Pérez-Taboada I. et al, (2020), Mov Disord, 35, 1636 - 1648

Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s

Brimblecombe KR. et al, (2020)

Impairment of Macroautophagy in Dopamine Neurons Has Opposing Effects on Parkinsonian Pathology and Behavior.

Hunn BHM. et al, (2019), Cell Rep, 29, 920 - 931.e7

Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter.

Condon MD. et al, (2019), Nat Commun, 10

Calbindin-D28K Limits Dopamine Release in Ventral but Not Dorsal Striatum by Regulating Ca2+ Availability and Dopamine Transporter Function.

Brimblecombe KR. et al, (2019), ACS Chem Neurosci, 10, 3419 - 3426

Load More

1
2
3
4
5

Include forthcoming?